Regarding future obesity treatment strategies implementing novel GIP/GPL-1 co-agonists that are emerging it is unclear whether every co-agonist will be as beneficial as and superior to single GLP-1R agonism. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.